Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 17/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 17/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22636019 | 0.91 | KCNK3 (0.68) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL22636305 | 0.89 | KCNK3 (0.74) | KCNK3KCNK9 | |
| SCHEMBL19807672 | 0.88 | KCNK3 (0.66) | KCNK3KCNK9 | |
| SCHEMBL19807752 | 0.88 | KCNK3 (0.75) | KCNK3KCNK9 | |
| SCHEMBL22916216 | 0.88 | KCNK3 (0.74) | KCNK3KCNK9KDM4E | |
| SCHEMBL19807756 | 0.87 | KCNK3 (0.75) | KCNK3KCNK9 | |
| SCHEMBL22916213 | 0.87 | KCNK3 (0.69) | KCNK3KCNK9 | |
| SCHEMBL22636021 | 0.87 | KCNK3 (0.77) | KCNK3KCNK9KDM4E | |
| SCHEMBL19807492 | 0.87 | KCNK3 (0.75) | KCNK3KCNK9 | |
| SCHEMBL19807676 | 0.87 | KCNK3 (0.75) | KCNK3KCNK9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |